EGFR and non-small cell lung carcinoma: We describe a cohort of patients with early-stage resected EGFR-positive NSCLC with mature follow-up data predating adjuvant osimertinib, using patients with wildtype EGFR NSCLC diagnosed in the same time period as a comparator, to discern clinicopathologic characteristics and recurrence patterns.